Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX as Headache Prophylaxis in Chinese Patients With Chronic Migraine
NCT03193359Phase 3Withdrawn
- Sponsor
- Allergan
- Start
- Jan 2018
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of onabotulinumtoxinA in chronic migraine, sponsored by Allergan. Primary endpoints: Number of Participants with Adverse Events (AEs) at 24 weeks, Percentage of Participants with AEs Leading to Discontinuation at 24 weeks and 3 more. Planned start Jan 2018; status: withdrawn.
02
Drugs
onabotulinumtoxinA
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT03193359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193359.